Literature DB >> 12958170

Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors.

Rama Pai1, Toshikazu Nakamura, Woo S Moon, Andrzej S Tarnawski.   

Abstract

Colorectal cancer is the second most frequent cancer in the Western world, often lethal when invasion and/or metastasis occur. In addition to hepatocyte growth factor (HGF), colon cancer invasion may be driven by prostaglandins, especially the E2 series (PGE2), generated by the cyclooxygenase-2 (Cox-2) enzyme. While concentration of PGE2 as well as expression of Cox-2, HGF receptor (c-Met-R), epidermal growth factor receptor (EGFR), and beta-catenin are all dramatically increased in colon cancers and implicated in their growth and invasion, the precise role of PGE2 in the latter process remains unclear. Here we provide evidence that PGE2 transactivates c-Met-R (contingent upon functional EGFR), increases tyrosine phosphorylation and nuclear accumulation of beta-catenin, and induces urokinase-type plasminogen activator receptor (uPAR) mRNA expression. This is accompanied by increased beta-catenin association with c-Met-R and enhanced colon cancer cell invasiveness. Inactivation of EGFR and c-Met-R significantly reduced PGE2-induced cancer cell invasiveness. Clinical relevance of these findings is confirmed by our immunohistochemical studies demonstrating that cancer cells in the invasive front overexpress Cox-2, c-Met-R, and beta-catenin. Our findings explain a functional relationship between prostaglandins, EGFR, and c-Met-R in colon cancer growth and invasion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12958170     DOI: 10.1096/fj.02-1011com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  40 in total

1.  The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice.

Authors:  Kristy A Bauman; Scott H Wettlaufer; Katsuhide Okunishi; Kevin M Vannella; Joshua S Stoolman; Steven K Huang; Anthony J Courey; Eric S White; Cory M Hogaboam; Richard H Simon; Galen B Toews; Thomas H Sisson; Bethany B Moore; Marc Peters-Golden
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

2.  Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells.

Authors:  Qiang Zhen; Jun-Feng Liu; Jia-Bao Liu; Ren-Feng Wang; Wei-Wei Chu; Ya-Xiao Zhang; Guo-Liang Tan; Xiao-Jian Zhao; Bao-Lei Lv
Journal:  Cancer Biol Ther       Date:  2015-04-01       Impact factor: 4.742

3.  Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma.

Authors:  Jurriaan B Tuynman; Christianne J Buskens; Kristel Kemper; Fiebo J W ten Kate; G Johan A Offerhaus; Dirk J Richel; J Jan B van Lanschot
Journal:  Ann Surg       Date:  2005-12       Impact factor: 12.969

Review 4.  ERBBs in the gastrointestinal tract: recent progress and new perspectives.

Authors:  William H Fiske; David Threadgill; Robert J Coffey
Journal:  Exp Cell Res       Date:  2008-11-07       Impact factor: 3.905

5.  Nemosis of fibroblasts is inhibited by benign HaCaT keratinocytes but promoted by malignant HaCaT cells.

Authors:  Kati Räsänen; Pertteli Salmenperä; Marc Baumann; Ismo Virtanen; Antti Vaheri
Journal:  Mol Oncol       Date:  2008-10-01       Impact factor: 6.603

6.  Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft.

Authors:  Manjinder Kaur; Balaiya Velmurugan; Alpna Tyagi; Gagan Deep; Suchitra Katiyar; Chapla Agarwal; Rajesh Agarwal
Journal:  Mol Cancer Ther       Date:  2009-07-28       Impact factor: 6.261

7.  Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy.

Authors:  N Banu; A Buda; S Chell; D Elder; M Moorghen; C Paraskeva; D Qualtrough; M Pignatelli
Journal:  Cell Prolif       Date:  2007-10       Impact factor: 6.831

8.  Co-expression of cox-2, C-met and beta-catenin in cells forming invasive front of gallbladder cancer.

Authors:  Woo Sung Moon; Ho Sung Park; Ho Lee; Rama Pai; Andrzej S Tarnawski; Kyung Ryoul Kim; Kyu Yun Jang
Journal:  Cancer Res Treat       Date:  2005-06-30       Impact factor: 4.679

9.  Multi-Target Approaches in Colon Cancer Chemoprevention Based on Systems Biology of Tumor Cell-Signaling.

Authors:  Suresh Guruswamy; Chinthalapally V Rao
Journal:  Gene Regul Syst Bio       Date:  2008-05-02

10.  Prostaglandin E2-induced colonic secretion in patients with and without colorectal neoplasia.

Authors:  Nicolai Kaltoft; Maria C Tilotta; Anne-Barbara Witte; Philip S Osbak; Steen S Poulsen; Niels Bindslev; Mark B Hansen
Journal:  BMC Gastroenterol       Date:  2010-01-26       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.